Biotechnology Investment fund raises stake in private companies
This article was originally published in Clinica
Biotechnology Investment Limited (BIL), one of the UK's few investment companies concentrating on development-stage companies in the biotechnology sector, saw its investments in quoted companies fall by 38% in value, to $204 million last year. Its investments in private companies rose, however, by 7%, to $83 million.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.